Edwards Lifesciences (NYSE:EW) Rating Lowered to Hold at Wall Street Zen

Edwards Lifesciences (NYSE:EW) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other research firms have also recently issued reports on EW. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. TD Cowen reiterated a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Barclays reiterated an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Finally, Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $96.39.

Edwards Lifesciences Stock Down 0.1%

Shares of Edwards Lifesciences stock opened at $94.31 on Friday. Edwards Lifesciences has a one year low of $72.30 and a one year high of $94.47. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock’s 50-day moving average is $85.61 and its 200 day moving average is $83.57. The firm has a market cap of $54.31 billion, a price-to-earnings ratio of 50.17, a PEG ratio of 2.37 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 3 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $91.40, for a total value of $56,576.60. Following the sale, the vice president owned 40,411 shares of the company’s stock, valued at approximately $3,693,565.40. This represents a 1.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 58,977 shares of company stock worth $4,921,803. 0.31% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. MV Capital Management Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth $26,000. Hanson & Doremus Investment Management acquired a new position in shares of Edwards Lifesciences during the first quarter valued at about $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $27,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $28,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.